S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Can Carnival Cruise Lines Set Sail For New Highs? 
Banking Nightmare (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Banking Nightmare (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Finland's NATO membership: What's next?
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Can Carnival Cruise Lines Set Sail For New Highs? 
Banking Nightmare (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Banking Nightmare (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Finland's NATO membership: What's next?
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Can Carnival Cruise Lines Set Sail For New Highs? 
Banking Nightmare (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Banking Nightmare (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Finland's NATO membership: What's next?
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Can Carnival Cruise Lines Set Sail For New Highs? 
Banking Nightmare (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Banking Nightmare (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Finland's NATO membership: What's next?
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
ASX:DXS

Dexus - DXS Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
5.01 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.71%
Price Target
N/A

DXS stock logo

About Dexus (ASX:DXS) Stock

Dexus is one of Australia's leading real estate groups, proudly managing a high-quality Australian property portfolio valued at $44.3 billion. We believe that the strength and quality of our relationships will always be central to our success and are deeply committed to working with our customers to provide spaces that engage and inspire. We invest only in Australia, and directly own $16.5 billion of office and industrial properties. We manage a further $15.6 billion of office, retail, industrial and healthcare properties for third party clients. The group's $11.4 billion development pipeline provides the opportunity to grow both portfolios and enhance future returns. With 1.6 million square metres of office workspace across 51 properties, we are Australia's preferred office partner. Dexus is a Top 50 entity by market capitalisation listed on the Australian Securities Exchange (trading code: DXS) and is supported by more than 29,000 investors from 24 countries. With 36 years of expertise in property investment, development and asset management, we have a proven track record in capital and risk management, providing service excellence to tenants and delivering superior risk adjusted returns for investors.

Receive DXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dexus and its competitors with MarketBeat's FREE daily newsletter.

DXS Stock News Headlines

Dexus Finance Pty Limited: Appendix 3Y - Elana Rubin
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Dexus Finance Pty Limited: 2022 AGM Chair and CEO Address
Dexus Finance Pty Limited: September 2022 quarter update
Dexus Finance Pty Limited: 2022 Notice of Annual General Meeting
Dexus (DXS.AX)
Dexus Finance Pty Limited: Appendix 3G, 3H and 3Y
Dexus - Stock Sustainability DXS
Dexus - Stock Ownership DXS
See More Headlines
Receive DXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dexus and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
REIT - Diversified
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
559
Year Founded
N/A

Profitability

Net Income
$835.80 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.31 billion
Book Value
A$12.35 per share

Miscellaneous

Outstanding Shares
1,080,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
0.67

Key Executives

  • Mr. Darren Joseph Steinberg BEc
    F.A.C.I.D., FAICD, FAPI, FRICS, CEO & Exec. Director of DEXUS Funds Management Limited
  • Ms. Keir L. Barnes
    Chief Financial Officer
  • Mr. Ross G. Du Vernet
    Chief Investment Officer of Dexus Funds Management Limited
  • Ms. Deborah Claire Coakley
    Exec. Gen. Mang. of Funds Management
  • Ms. Melanie Bourke
    Chief Operating Officer of Dexus Funds Management Limited
  • Ms. Rowena Causley
    Head of Investor Relations
  • Mr. Brett D. Cameron B.A.
    GAICD, L.L.B., Gen. Counsel & Company Sec. of Dexus Funds Management Limited
  • Mr. Paul Oates
    Group Gen. Mang. of Devel.
  • Mr. Christopher Hynes
    Head of Office & Industrial Leasing
  • Mr. Richard Garing
    Regional Gen. Mang. of Office & Industrial













DXS Stock - Frequently Asked Questions

How often does Dexus pay dividends? What is the dividend yield for Dexus?

Dexus announced a Final dividend on Tuesday, June 28th. Investors of record on Monday, August 29th will be given a dividend of 0.252 per share on Monday, August 29th. This represents a dividend yield of 2.65%. The ex-dividend date of this dividend is Tuesday, June 28th. This is an increase from the stock's previous Final dividend of A$0.23.
Read our dividend analysis for DXS
.

Is Dexus a good dividend stock?

Dexus (ASX:DXS) pays an annual dividend of A$0.56 per share and currently has a dividend yield of 6.71%. DXS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 73.68%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for DXS.

What other stocks do shareholders of Dexus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dexus investors own include Metrics Master Income Trust (MXT), First Quantum Minerals (FM), EastGroup Properties (EGP), The Carlyle Group (CG) and Abacus Property Group (ABP).

What is Dexus' stock symbol?

Dexus trades on the ASX under the ticker symbol "DXS."

How much money does Dexus make?

Dexus (ASX:DXS) has a market capitalization of $0.00 and generates $1.31 billion in revenue each year. The company earns $835.80 million in net income (profit) each year or A$0.76 on an earnings per share basis.

How many employees does Dexus have?

The company employs 559 workers across the globe.

How can I contact Dexus?

Dexus' mailing address is Australia Square, L 25 264-278 George St, SYDNEY, NSW 2000, Australia. The official website for the company is www.dexus.com. The company can be reached via phone at +61-2-90171100.

This page (ASX:DXS) was last updated on 3/28/2023 by MarketBeat.com Staff